Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where J. Berth-Jones is active.

Publication


Featured researches published by J. Berth-Jones.


The Lancet | 1991

Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis

J.M. Sowden; B.R. Allen; J. Berth-Jones; R.A.C. Graham-Brown; Richard Motley; Andrew Yule Finlay; Mir-saeed Salek; R. Marks; J.S. Ross; R.D.R. Camp

A few patients remain severely affected by atopic dermatitis into adult life despite treatment with systemic steroids, azathioprine, and photochemotherapy. 33 patients took part in a double-blind, placebo-controlled, crossover study to assess the efficacy and safety of cyclosporin (5 mg/kg per day) in adults with severe refractory atopic dermatitis. Treatments were given for eight weeks each with one group (n = 16) receiving placebo followed by cyclosporin and another (n = 17) receiving cyclosporin and then placebo. Disease activity, extent of disease, sleep and itch, topical steroid use, and adverse events were assessed every two weeks. Both extent and activity of dermatitis were significantly improved (p less than 0.001) as were subjective measures of disease. 20 patients receiving cyclosporin reported adverse events compared with 8 taking placebo, although no patient required withdrawal from the study. Cyclosporin therapy led to an increase in the mean serum urea, creatinine, and bilirubin concentrations, although only the rise in bilirubin was significant (p = 0.001). Our results confirm that cyclosporin is a safe and effective short-term treatment for severe, refractory atopic dermatitis.


Journal of The American Academy of Dermatology | 1992

Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris

W.J. Cunliffe; J. Berth-Jones; Alain Claudy; Geoffrey Fairiss; David Goldin; David Gratton; Catriona A. Henderson; Colin A. Holden; W. Stuart Maddin; Jean-Paul Ortonne; Marjorie Young

BACKGROUND Topical vitamin D analogues have been reported to be an effective treatment in patients with psoriasis. Comparative studies with existing treatments are required. OBJECTIVE Our purpose was to compare the effectiveness of calcipotriol (50 micrograms/gm) and betamethasone 17-valerate (1 mg/gm) ointments twice daily in the treatment of stable plaque psoriasis. METHODS This study was a randomized, double-blind comparison over 6 weeks in 409 patients. Efficacy, as measured by the Psoriasis Area and Severity Index (PASI), and safety were assessed at 2, 4, and 6 weeks. RESULTS Reduction of PASI was statistically significant at all time points for both treatments but there were no significant between-treatment differences. At the completion of 6 weeks of treatment, the mean PASI reduction was 5.50 for calcipotriol and 5.32 for betamethasone (95% confidence interval [CI] -0.40 to 0.78). Analysis of patient assessment at 6 weeks showed clearance or marked improvement in 61.2% of the calcipotriol patients and 50.5% with betamethasone (95% CI 1.4 to 20.8). Calcipotriol produced significantly more local side effects (19.5% compared with 3.9%, p less than 0.001); however, these were minimal leading to withdrawal in only 3 of 205 patients. CONCLUSION Calcipotriol ointment was as effective as betamethasone 17-valerate ointment as measured by the PASI and superior as measured by self-assessment in patients with stable plaque psoriasis. Both treatments were well tolerated.


The Lancet | 1993

Placebo-controlled trial of essential fatty acid supplementation in atopic dermatitis

J. Berth-Jones; R.A.C. Graham-Brown

Treatment of atopic dermatitis with essential fatty acids remains controversial. A double-blind, placebo-controlled, parallel-group study was done to investigate the response of patients with atopic dermatitis to essential fatty acid supplements. Patients with atopic dermatitis were randomised to receive evening primrose oil, evening primrose oil and fish oil, or placebo for 16 weeks. Disease activity was monitored by clinical severity scores recorded by the investigator, topical steroid requirement, and symptom scores recorded by subjects. Of 123 subjects recruited, 102 completed the treatment period. No improvement with active treatment was demonstrated. Our study, which avoided the methodological and analytical problems of previous studies, found no effect of essential fatty acid supplementation in atopic dermatitis.


British Journal of Dermatology | 1995

Novel cycle changes in scalp hair are caused by etretinate therapy

J. Berth-Jones; P.E. Hutchinson

The scalp hair of 15 patients, who were treated with etretinate for at least 6 months, was investigated, with the aims of confirming the previously described reduction in the duration of anagen and establishing the mechanism of etretinate alopecia. An increase in hair shedding rate and an increase in plucked telogen count, both of which continued for 6 months of treatment, were found, whereas there was no significant increase in the proportion of new, or regrowing, anagen hairs in a cut sample(NAH). The sustained decrease in the duration of anagen was confirmed, and it was further shown that this decrease was progressive. This would appear to be the main cause of the observed increased shedding associated with etretinate treatment. In relation to the mechanism of the alopecia, it was concluded that an arrest at the onset of anagen and a follicular anchorage defect in telogen were causes. The evidence for an arrest at the onset of anagen was a failure of NAH to rise on treatment, and a large increase in NAH on stopping treatment. The evidence for a follicular anchorage defect was a rise in shed rate very early in treatment, and an observed shed rate greater than expected, on the basis of plucked telogen results, later in treatment.


British Journal of Dermatology | 2006

Prevalence of atopic dermatitis in Leicester : a study of methodology and examination of possible ethnic variation

R.L. Neame; J. Berth-Jones; J.J. Kurinczuk; R.A.C. Graham-Brown

A study was undertaken to investigate and compare various methods of estimating the prevalence of atopic dermatitis (AD), and to investigate a possible ethnic difference in our local community. Preschool children attending routine child health surveillance clinics and Social Services day nurseries were examined by a trained observer, and their parents were interviewed. In addition, general practice records from a health centre were scrutinized.


British Journal of Dermatology | 1995

Cryotherapy of common viral warts at intervals of 1, 2 and 3 weeks

J.F. Bourke; J. Berth-Jones; P.E. Hutchinson

We studied the efficacy, and time to clearance, of more frequent cryotherapy of viral warts, by randomizing 225 patients to receive treatment at 1‐, 2‐ or 3‐weekly intervals. The mean times to clearance of warts in each group were 5.5, 9.5 and 15 weeks in the weekly, 2‐weekly and 3‐weekly groups, respectively (P < 0.01). Cure rates after 3 months correlated with frequency of treatment (P < 0.05). After 3 months, 43% (66% of non‐defaulters) had cleared in the group treated weekly, 37% (47%) of the group treated every 2 weeks, and 26% (30%) of those treated every 3 weeks. The mean numbers of treatments needed to achieve clearance were similar in each group (5.5, 4.75 and 5 treatments). After 12 treatments, cure rates were similar for all three groups: 43% for the weekly‐ treated group (3 months), 48% for the 2‐weekly group (6 months), and 44% for the 3‐weekly group (9 months). Percentage cure is related to the number of treatments received, and independent of the interval between treatments. A more rapid cure may, therefore, be achieved by more frequent treatment.


British Journal of Dermatology | 1994

Value of a second freeze-thaw cycle in cryotherapy of common warts.

J. Berth-Jones; J.F. Bourke; H. Eglitis; C. Harper; P. Kirk; S. Pavord; R. Rajapakse; P. Weston; T. Wiggins; P.E. Hutchinson

A study of open, randomized, parallel‐group design was performed to investigate the impact of a second freeze‐thaw cycle on the cure rate, at 3 months, from cryotherapy of common warts on the hands and feet.


British Journal of Dermatology | 1993

Urine calcium excretion during treatment of psoriasis with topical calcipotriol

J. Berth-Jones; J.F. Bourke; S.J. Iqbal; P.E. Hutchinson

Urine calcium excretion is a very sensitive method of detecting vitamin D intoxication, and may rise in the absence of any apparent change in the serum level. Little attention has been paid to urine calcium levels during the large trials performed to assess the efficacy and safety of calcipotrioi in psoriasis vulgaris. There are some urine calcium data from short‐term studies of average dose rates of calcipotriol. However, there are no published data on long‐term usage, nor on the use of dose rates at the upper end of the licensed range (100 g/week).


British Journal of Dermatology | 1993

High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris

J.F. Bourke; J. Berth-Jones; S.J. Iqbal; P.E. Hutchinson

Summary Ten patients with extensive plaque psoriasis were treated with calcipotriol ointment (50 μg/g) for 2 weeks (200 g for 1 week, followed by 300 g during the second week). Mean improvement in psoriasis area and severity index (PASI) was 71%. Mean 24 h urine calcium rose from 4.79 mmol/24 h to 7.27 mmol/24 h (P<0.000l). Urine calcium returned towards baseline after stopping calcipotriol. Mean serum calcium also rose slightly, hut significantly, from 2.26 mmol/l to 2.32 mmol/l (P<0.005). and fell again in the washout phase. Individual serum calcium values remained within the normal range throughout the study. Topical calcipotriol is an effective, rapidly acting and safe in‐patient treatment for extensive plaque psoriasis.


Clinical and Experimental Dermatology | 1995

Benign familial chronic pemphigus (Hailey-Hailey disease) responds to cyclosporin

J. Berth-Jones; S.G. Smith; R.A.C. Graham-Brown

A patient with benign familial chronic pemphigus was treated with cyclosporin at a dose ranging from 2.8 to 3.4 mg/kg per day. There was a clear improvement in the area of skin affected and in exudation and soreness. The response was maintained for 24 weeks but there was a gradual deterioration after treatment was stopped.

Collaboration


Dive into the J. Berth-Jones's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

P.E. Hutchinson

Leicester Royal Infirmary

View shared research outputs
Top Co-Authors

Avatar

J.F. Bourke

Leicester Royal Infirmary

View shared research outputs
Top Co-Authors

Avatar

S.J. Iqbal

Leicester Royal Infirmary

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

B. Dure‐Smith

Leicester Royal Infirmary

View shared research outputs
Top Co-Authors

Avatar

D.A. Burns

Leicester Royal Infirmary

View shared research outputs
Top Co-Authors

Avatar

S. George

Leicester Royal Infirmary

View shared research outputs
Top Co-Authors

Avatar

A. Kurwa

Leicester Royal Infirmary

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge